Skip to main content

Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Agency: National Institutes of Health

Assistance Listings
  • 93.394 -- Cancer Detection and Diagnosis Research

Forecasted opportunityLast Updated: Jul 14, 2026

Important dates

  • Forecasted post date: January 15, 2027
  • Forecasted application due date: June 4, 2027
  • Forecasted award date: April 1, 2028
  • Forecasted project start date: April 15, 2028
  • Fiscal Year: 2028

Award details

  • Expected project funding: $5,400,000
  • Expected awards: 23

Award min.

Not specified

Award max.

$150,000

  • Funding opportunity number:RFA-CA-28-001
  • Cost sharing or matching requirement:No
  • Funding instrument type:
    • Grant
  • Opportunity Category:Discretionary
  • Opportunity Category Explanation:Not specified
  • Category of Funding Activity:
    • Health
  • Category Explanation:Not specified

History

  • Forecast posted date: July 14, 2026
  • Archive date: Not specified
  • Version: 1

View version history on Grants.gov

Summary

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies for cancer research or clinical care. The emphasis of this NOFO is on early-stage projects proposing proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. 

Well-suited applications must offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. 

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. 

Eligibility

Business

  • For-profit organizations other than small businesses
  • Small businesses

Miscellaneous

  • Other

Government

  • City or township governments
  • Federally recognized Native American tribal governments
  • County governments
  • State governments
  • Special district governments
  • Public and Indian housing authorities

Nonprofit

  • Other Native American tribal organizations
  • Nonprofits non-higher education with 501(c)(3)
  • Nonprofits non-higher education without 501(c)(3)

Education

  • Independent school districts
  • Public and state institutions of higher education
  • Private institutions of higher education

Additional information on eligibility

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

Documents

No documents are currently available.

Agency contact information

Email: NCI-IMAT@nih.gov

NCI-IMAT@nih.gov

IMAT Program Contact 240-255-0917

Link to additional information

No additional information is available

HHS.gov

An official website of the U.S. Department of Health and Human Services

Looking for U.S. government information and services? Visit USA.gov